spironolactone has been researched along with aliskiren in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kikkawa, K | 1 |
| Lindner, T | 1 |
| Bednarski, R; Donderski, R; Heleniak, Z; Lizakowski, S; Manitius, J; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Sulikowska, B; Tylicki, L | 1 |
| Fukuda, S; Sato, A | 1 |
| De Mello, WC | 1 |
| di Mario, C; Francis, DP; Hayward, C; Krum, H; Lyon, AR; Ozdemir, BA; Patel, HC; Rosen, SD | 1 |
3 review(s) available for spironolactone and aliskiren
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Antihypertensive drugs in clinical development].
Topics: Amides; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Eplerenone; Fumarates; Heterocyclic Compounds, 3-Ring; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2006 |
Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation.
Topics: Amides; Antihypertensive Agents; Benzimidazoles; Benzopyrans; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Control Groups; Double-Blind Method; Drug Resistance; Eplerenone; Ethanolamines; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Nebivolol; Oxadiazoles; Placebo Effect; Placebos; Randomized Controlled Trials as Topic; Regression Analysis; Research Design; Spironolactone; Sympathectomy; Tetrazoles; Treatment Outcome | 2015 |
2 trial(s) available for spironolactone and aliskiren
| Article | Year |
|---|---|
The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?.
Topics: Adult; Albuminuria; Amides; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Comorbidity; Cross-Over Studies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Fumarates; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Renin; Renin-Angiotensin System; Severity of Illness Index; Spironolactone; Telmisartan; Treatment Outcome | 2012 |
Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
Topics: Aged; Albuminuria; Aldosterone; Amides; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Female; Fumarates; Humans; Hypertension; Incidence; Longitudinal Studies; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Time Factors | 2013 |
2 other study(ies) available for spironolactone and aliskiren
| Article | Year |
|---|---|
Aliskiren combined with losartan in diabetes and nephropathy.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Fumarates; Humans; Losartan; Mineralocorticoid Receptor Antagonists; Proteinuria; Renin; Spironolactone | 2008 |
Spironolactone enhances the beneficial effect of aliskiren on cardiac structural and electrical remodeling in TGR(mRen2)27 rats.
Topics: Amides; Animals; Blood Pressure; Coronary Vessels; Echocardiography; Fibrosis; Fumarates; Heart; Heart Conduction System; Injections, Intraperitoneal; Male; Rats, Transgenic; Renin; Rest; Spironolactone; Systole; Ventricular Remodeling | 2015 |